A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males

Trial Profile

A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease; Dementia; Down syndrome; Lewy body disease; Vascular dementia
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 12 Mar 2015 Status changed from recruiting to completed.
    • 21 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 27 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top